Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types.CAPTN-3 antibodies are designed to promote innate-like antitumor functions by NK and CD8 T cells, through conditional activation of the anti-CD3 arm at the TME, blockade of NKG2A, and targeting tumor-specific antigens, potentially leading to improved responses in resistant cancer patients and overcoming the limita ...